Plus Therapeutics Inc (PSTV) - Financial and Strategic SWOT Analysis Review

December 2019 | 45 pages | ID: P2B01A43B72CEN
GlobalData

Abstracts

Plus Therapeutics Inc (PSTV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Plus Therapeutics Inc (Plus Therapeutics) is a developmental stage pharmaceutical company which focuses on discovery, development, and manufacturing of complex and innovative treatments for patients with cancer and other life-threatening diseases. Its pipeline products include Doceplus, a patented albumin-stabilized Pegylated liposomal formulation of docetaxel and Doxoplus, a complex, injectable, generic Pegylated liposomal formulation of doxorubicin. The company uses its proprietary nanotechnology platform to reformulate and improve conventional chemotherapeutics to provide meaningful benefits to healthcare providers and patients. Plus is headquartered in Irvine, Texas the US.

Plus Therapeutics Inc Key Recent Developments

Nov 14,2019: Plus Therapeutics reports third quarter 2019 financial and business results
Jul 16,2019: Cytori will become Plus Therapeutics
May 14,2019: Cytori reports Q1 2019 business and financial results
Apr 01,2019: Cytori reports fourth quarter and full year 2018 business and financial results
Nov 14,2018: Cytori reports Q3 2018 business and financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Plus Therapeutics Inc - Key Facts
Plus Therapeutics Inc - Key Employees
Plus Therapeutics Inc - Key Employee Biographies
Plus Therapeutics Inc - Major Products and Services
Plus Therapeutics Inc - History
Plus Therapeutics Inc - Company Statement
Plus Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Plus Therapeutics Inc - Business Description
R&D Overview
Plus Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Plus Therapeutics Inc - Strengths
Plus Therapeutics Inc - Weaknesses
Plus Therapeutics Inc - Opportunities
Plus Therapeutics Inc - Threats
Plus Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Plus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Plus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Plus Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Nov 14, 2019: Plus Therapeutics reports third quarter 2019 financial and business results
Jul 16, 2019: Cytori will become Plus Therapeutics
May 14, 2019: Cytori reports Q1 2019 business and financial results
Apr 01, 2019: Cytori reports fourth quarter and full year 2018 business and financial results
Nov 14, 2018: Cytori reports Q3 2018 business and financial results
Aug 14, 2018: Cytori reports Q2 2018 business and financial results
Aug 09, 2018: Cytori reports publication of interim pilot data for cell therapy in vocal fold scarring
May 10, 2018: Cytori Reports Q1 2018 Business and Financial Results
Mar 08, 2018: Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Plus Therapeutics Inc, Key Facts
Plus Therapeutics Inc, Key Employees
Plus Therapeutics Inc, Key Employee Biographies
Plus Therapeutics Inc, Major Products and Services
Plus Therapeutics Inc, History
Plus Therapeutics Inc, Other Locations
Plus Therapeutics Inc, Subsidiaries
Plus Therapeutics Inc, Key Competitors
Plus Therapeutics Inc, Ratios based on current share price
Plus Therapeutics Inc, Annual Ratios
Plus Therapeutics Inc, Annual Ratios (Cont...1)
Plus Therapeutics Inc, Interim Ratios
Plus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Plus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Plus Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Plus Therapeutics Inc, Performance Chart (2014 - 2018)
Plus Therapeutics Inc, Ratio Charts
Plus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Plus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

SERVA Electrophoresis GmbH
Teva Pharmaceuticals USA Inc
Healeon Medical Inc
GID Group Inc
Human Med AG
Tissue Genesis Inc
AdiSave Inc